OCS

NASDAQ · Pharmaceuticals

Oculis Holding Ag

Small-Cap Stocks Pharmaceutical Stocks Healthcare Stocks

$11.52

-0.15 (-1.29%)

As of Jun 23, 2:00 PM ET ·

OCS News1 articles

Oculis Shares Plunge as Eye Drop Fails Key Trial Goal

Oculis shares tumbled 23.4% after two Phase 3 trials of OCS-01 eye drops for diabetic macular edema failed to meet the main vision goal. The company will not pursue U.S. approval for this indication.